Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969838 · ClinicalTrials.gov registry record · Phase 3
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT01969838 is a Phase 3 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 432 participants.
The verdict
NCT01969838, a Phase 3 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 216 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those participants planning to continue treatment with MMB following the end of the study, the Early Study Drug Discontinuation (ESDD), 30-day, 12-Week, and survival follow-up visits are not required.
Interventions
- DRUG Ruxolitinib
- DRUG Momelotinib
- DRUG Placebo to match momelotinib
- DRUG Placebo to match ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2013-12-06 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969838
The ClinicalTrials.gov registry entry for NCT01969838 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ruxolitinib is the first listed.
NCT01969838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969838 about?
NCT01969838 is a clinical study titled "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis". This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhi...
What is the current status of trial NCT01969838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2013-12-06. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT01969838?
The interventions under investigation include: Ruxolitinib (DRUG), Momelotinib (DRUG), Placebo to match momelotinib (DRUG), Placebo to match ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01969838?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.